An ongoing dialogue on HIV/AIDS, infectious diseases,
April 30th, 2025
On-Service ID Link-o-Rama — Osmosis Edition
First-year ID fellows this time of year bring a lot to inpatient consult rotations. Years of high-volume inpatient care have sharpened their clinical instincts, and at this point they have an impressive fund of ID knowledge. Plus, the fellow on our current rotation gets along great with everyone — patients and consulting clinicians alike — […]
April 18th, 2025
SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultations — and for good reason: when mismanaged or complicated, it can lead to high morbidity, a myriad of complications, and a disturbingly high mortality rate. Despite its […]
April 11th, 2025
Looking Back at a Defunct ID Meeting — and Ahead to a Thriving One
Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising “bug-drug” studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, […]
April 3rd, 2025
Gepotidacin — New Antibiotic or Rare Tropical Bird?
Imagine you’re birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly: Look, it’s the elusive Blujepa! A rare sighting! No, not a real bird, but the brand name of gepotidacin, something rarer — and arguably more exciting — than […]
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.